Keyword : first line therapy
Advantages and risks of using CDK4/6 inhibitors, including palbociclib, in first-line therapy for HR+ metastatic breast cancerДата: 2024-12-31
Prospects for the use of pembrolizumab in the treatment of previously untreated patients with advanced malignant pleural mesotheliomaAuthor:Nemish I.L. Т. 13, № 3 (51)
